The estimated Net Worth of Thomas T. Thomas is at least $246 mil dollars as of 21 September 2021. Mr. Thomas owns over 3,834 units of Opiant Pharmaceuticals Inc stock worth over $229,422 and over the last 5 years he sold OPNT stock worth over $16,220. In addition, he makes $0 as Director at Opiant Pharmaceuticals Inc.
Thomas has made over 5 trades of the Opiant Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,834 units of OPNT stock worth $38,340 on 21 September 2021.
The largest trade he's ever made was exercising 3,834 units of Opiant Pharmaceuticals Inc stock on 21 September 2021 worth over $38,340. On average, Thomas trades about 1,233 units every 38 days since 2019. As of 21 September 2021 he still owns at least 11,110 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Mr. Thomas stock trades at the bottom of the page.
Thomas T. Thomas serves as Director of the Company. Mr. Thomas has over 25 years of financial experience in biotechnology, packaged goods, financial services and non-profit organizations. Since 2011, Mr. Thomas has been self-employed providing financial, investment and risk management consulting services to a variety of technology, beverage and food and biotechnology companies. In 2009, Mr. Thomas joined the Stupski Foundation (“Stupski”), as its chief financial officer. In 2010, Mr. Thomas was promoted to chief operating officer and served as Stupski’s interim chief executive officer before leaving Stupski in late 2010 to pursue consulting opportunities. Prior to joining Stupski, Mr. Thomas spent 12 years at Genentech, Inc. (“Genentech”), serving as the company’s corporate treasurer from 2001 to 2006. His executive responsibilities at Genentech included treasury operations, cash and investment management, corporate finance, global procurement, enterprise risk management, business continuity and real estate finance and administration. From 1990 to 1994, Mr. Thomas was a manager of financial strategy with Del Monte Foods and he began his career in 1988 at GE Capital Corporation (“GE”) as an analyst in GE’s corporate finance group, which focused on leveraged buyouts and bankruptcy financing. Mr. Thomas currently serves on the board of trustees of the Cancer Prevention Institute of California and has previously served on the boards of the San Francisco Security Analysts and Hospitality House. He is also a mentor in the Ivy Exec Mentorship Network. Mr. Thomas is a Chartered Financial Analyst and received his Master of Business Administration from the University of Cincinnati, where he was a Graduate Fellow, and a Bachelor of Music from the University of Cincinnati’s College-Conservatory of Music.
Thomas's mailing address filed with the SEC is C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD. SUITE 400, SANTA MONICA, CA, 90401.
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen y Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include: